Beliefs about medicines’ association with endocrine therapy adherence in early breast cancer survivors in Croatia

Author:

Okroša Ana Dugonjić1,Silovski Tajana23,Plavetić Natalija Dedić23,Silovski Hrvoje34,Kovačić Ana5,Mucalo Iva6ORCID

Affiliation:

1. 1 Agency for Medicinal Products and Medical Devices of Croatia , Zagreb Croatia

2. 2 Department of Oncology , University Hospital Centre Zagreb , Zagreb , Croatia

3. 3 University of Zagreb , Medical School Zagreb , Croatia

4. 4 Department of Surgery , University Hospital Centre Zagreb , Zagreb , Croatia

5. 5 University of Zagreb Faculty of Food Technology and Biotechnology , Zagreb Croatia

6. 6 University of Zagreb Faculty of Pharmacy and Biochemistry , Zagreb Croatia

Abstract

Abstract This observational, cross-sectional study conducted at the University Hospital Centre Zagreb (UHC Zagreb) aimed to explore patients’ beliefs about adjuvant endocrine therapy (AET) as well as their association with non-adherence and sociodemographic and clinical factors. Out of 420 early breast cancer (BC) patients included in the study, 79.5 % perceived AET necessary and important for their health, as measured by the Belief About Medicines Questionnaire (BMQ), with the mean necessity score (20.4 ± 3.68) significantly higher than the mean concerns score (13 ± 4.81) (p < 0.001). Based on the Medication Adherence Report Scale (MARS-5), 44.4 % (n = 182) of the participants were non-adherers, out of which 63.2 % (n = 115) were unintentional and 36.8 % (n = 67) intentional non-adherers. Significantly higher concern beliefs were found among patients that were younger (p < 0.001), employed (p < 0.001), intentionally non-adherent to AET (p = 0.006), had a lower body-mass index (p = 0.005) and a higher level of education (p < 0.001), were premenopausal at the time of diagnosis (p < 0.001), taking tamoxifen treatment (p = 0.05) and receiving ovarian suppression (p < 0.001). Younger patients should be recognized as being at risk of non-adherence as they hold greater concern beliefs about medicines.

Publisher

Walter de Gruyter GmbH

Subject

Pharmaceutical Science,Pharmacology,General Medicine

Reference63 articles.

1. H. Sung, J. Ferlay, R. L. Siegel, M. Laversanne, I. Soerjomataram, A. Jemal and F. Bray, Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA Cancer J. Clin. 71(3) (2021) 209-249

2. H. Sung, J. Ferlay, R. L. Siegel, M. Laversanne, I. Soerjomataram, A. Jemal and F. Bray, Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA Cancer J. Clin. 71

3. (3) (2021) 209-249; https://doi.org/10.3322/caac.21660

4. European Cancer Information System, Estimates of cancer incidence and mortality in 2020; https://ecis.jrc.ec.europa.eu/; last access date May 15, 2023.

5. V. Foulon, P. Schöffski and P. Wolter, Patient adherence to oral anticancer drugs: An emerging issue in modern oncology, Acta Clin. Belg. 66(2) (2011) 85–96; https://doi.org/10.2143/ACB.66.2.2062525

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3